

Cristiano Noto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3691711/publications.pdf>

Version: 2024-02-01

75
papers

2,812
citations

279798

23
h-index

214800

47
g-index

83
all docs

83
docs citations

83
times ranked

3548
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal invariance of the positive and negative syndrome scale negative dimension in antipsychotic naïve first-episode schizophrenia. <i>Microbial Biotechnology</i> , 2022, 16, 581-586.	1.7	3
2	Unraveling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2022, 76, 559-564.	1.3	1
3	Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia. <i>Molecular Neurobiology</i> , 2022, 59, 3170-3182.	4.0	4
4	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
5	Is treatment-resistant schizophrenia associated with distinct neurobiological callosal connectivity abnormalities?. <i>CNS Spectrums</i> , 2021, 26, 545-549.	1.2	4
6	Esketamine for Postpartum Suicidality. <i>Biological Psychiatry</i> , 2021, 89, e35-e36.	1.3	2
7	Impairments in Peripheral Blood T Effector and T Regulatory Lymphocytes in Bipolar Disorder Are Associated with Staging of Illness and Anti-cytomegalovirus IgG Levels. <i>Molecular Neurobiology</i> , 2021, 58, 229-242.	4.0	29
8	Structural brain abnormalities in schizophrenia in adverse environments: examining the effect of poverty and violence in six Latin American cities. <i>British Journal of Psychiatry</i> , 2021, 218, 112-118.	2.8	10
9	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. <i>Schizophrenia Research</i> , 2021, , .	2.0	4
10	Clozapine-induced hepatotoxicity: A life threatening situation. <i>Schizophrenia Research</i> , 2021, 235, 3-4.	2.0	3
11	BDNF in antipsychotic naïve first episode psychosis: Effects of risperidone and the immune-inflammatory response system. <i>Journal of Psychiatric Research</i> , 2021, 141, 206-213.	3.1	12
12	Aging biological markers in a cohort of antipsychotic-naïve first-episode psychosis patients. <i>Psychoneuroendocrinology</i> , 2021, 132, 105350.	2.7	7
13	First Episode Psychosis and Schizophrenia Are Systemic Neuro-Immune Disorders Triggered by a Biotic Stimulus in Individuals with Reduced Immune Regulation and Neuroprotection. <i>Cells</i> , 2021, 10, 2929.	4.1	21
14	Schneider's first-rank symptoms as predictors of remission in antipsychotic-naïve first-episode psychosis. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 22-26.	1.7	10
15	The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. <i>Molecular Neurobiology</i> , 2020, 57, 778-797.	4.0	93
16	Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 677-683.	1.7	7
17	LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort. <i>Epigenomics</i> , 2020, 12, 1041-1051.	2.1	7
18	A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 721-730.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Patients with Schizophrenia Undergoing Gastric Bypass Surgery: a Case Series Study. <i>Obesity Surgery</i> , 2020, 30, 3813-3821.	2.1	4
20	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , 2020, 218, 195-200.	2.0	16
21	Blood gene expression changes after Risperidone treatment in an antipsychotic-naïve cohort of first episode of psychosis patients. <i>Schizophrenia Research</i> , 2020, 220, 285-286.	2.0	3
22	GENOME-WIDE DNA METHYLATION ANALYSIS IN A LONGITUDINAL COHORT OF ANTIPSYCHOTIC-NAIVE FIRST EPISODE OF PSYCHOSIS PATIENTS. <i>European Neuropsychopharmacology</i> , 2019, 29, S1007-S1008.	0.7	0
23	Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia. <i>Schizophrenia Research</i> , 2019, 208, 202-208.	2.0	14
24	Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial. <i>Trials</i> , 2019, 20, 199.	1.6	5
25	DGCR2 influences cortical thickness through a mechanism independent of schizophrenia pathogenesis. <i>Psychiatry Research</i> , 2019, 274, 391-394.	3.3	4
26	Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages. <i>NPJ Schizophrenia</i> , 2019, 5, 5.	3.6	16
27	Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals. <i>Schizophrenia Research: Cognition</i> , 2019, 16, 12-16.	1.3	5
28	Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naïve first episode psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 416-431.	0.7	67
29	How challenging is to manage agitated patients?. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 277-278.	1.7	1
30	Investigating brain structural patterns in first episode psychosis and schizophrenia using MRI and a machine learning approach. <i>Psychiatry Research - Neuroimaging</i> , 2018, 275, 14-20.	1.8	18
31	Accessing Gene Expression in Treatment-Resistant Schizophrenia. <i>Molecular Neurobiology</i> , 2018, 55, 7000-7008.	4.0	23
32	Leukocyte telomere length variation in different stages of schizophrenia. <i>Journal of Psychiatric Research</i> , 2018, 96, 218-223.	3.1	25
33	Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. <i>Communications Biology</i> , 2018, 1, 163.	4.4	17
34	Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naïve first episode of psychosis cohort. <i>Translational Psychiatry</i> , 2018, 8, 174.	4.8	49
35	Shorter leukocyte telomere length in patients at ultra high risk for psychosis. <i>European Neuropsychopharmacology</i> , 2017, 27, 538-542.	0.7	25
36	Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. <i>Metabolic Brain Disease</i> , 2017, 32, 1003-1016.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Oxidative and nitrosative stress biomarkers in chronic schizophrenia. <i>Psychiatry Research</i> , 2017, 253, 43-48.	3.3	43
38	Gene Expression Alterations Related To Mania And Psychotic Symptoms In Peripheral Blood of Patients with A First Episode of Psychosis. <i>European Neuropsychopharmacology</i> , 2017, 27, S403-S404.	0.7	0
39	New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage. <i>Comprehensive Psychiatry</i> , 2017, 73, 93-96.	3.1	13
40	Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls. <i>Revista Brasileira De Psiquiatria</i> , 2017, 39, 302-308.	1.7	26
41	Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, 11, 151-155.	1.4	10
42	Hair cortisol in drug-naïve first-episode individuals with psychosis. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 11-16.	1.7	15
43	Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia. <i>Scientific Reports</i> , 2016, 6, 38897.	3.3	135
44	Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis. <i>Translational Psychiatry</i> , 2016, 6, e908-e908.	4.8	26
45	Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis. <i>Molecular Neurobiology</i> , 2016, 53, 5701-5709.	4.0	59
46	Psychosis in Machado-Joseph Disease: Clinical Correlates, Pathophysiological Discussion, and Functional Brain Imaging. Expanding the Cerebellar Cognitive Affective Syndrome. <i>Cerebellum</i> , 2016, 15, 483-490.	2.5	13
47	The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 134-144.	4.8	137
48	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. <i>Molecular Neurobiology</i> , 2016, 53, 2927-2935.	4.0	40
49	Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 280-288.	1.7	19
50	Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 168-176.	1.7	61
51	Effects of Risperidone on Cytokine Profile in Drug-Naive First-Episode Psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu042-pyu042.	2.1	77
52	Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis. <i>Schizophrenia Research</i> , 2015, 166, 225-230.	2.0	34
53	Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 441-446.	2.6	14
54	Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. <i>Journal of Psychiatric Research</i> , 2015, 68, 210-216.	3.1	51

#	ARTICLE	IF	CITATIONS
55	Effects of depression on the cytokine profile in drug naïve first-episode psychosis. <i>Schizophrenia Research</i> , 2015, 164, 53-58.	2.0	48
56	High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 422-429.	2.6	69
57	Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis. <i>European Neuropsychopharmacology</i> , 2015, 25, 2416-2425.	0.7	23
58	Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis. <i>Journal of Psychiatric Research</i> , 2015, 71, 89-96.	3.1	28
59	Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 229, 702-707.	3.3	22
60	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. <i>Psychiatry Research - Neuroimaging</i> , 2015, 234, 84-89.	1.8	16
61	Omics-based depression and inflammation research. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 1-2.	1.7	8
62	Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 336-339.	1.7	42
63	PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia. <i>PLoS ONE</i> , 2014, 9, e87686.	2.5	14
64	Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression. <i>NeuroImmunoModulation</i> , 2014, 21, 131-139.	1.8	40
65	What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS. <i>Schizophrenia Research</i> , 2014, 158, 277-278.	2.0	3
66	Changes in gene expression and methylation in the blood of patients with first-episode psychosis. <i>Schizophrenia Research</i> , 2014, 159, 358-364.	2.0	35
67	Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: A follow-up study in antipsychotic-naïve patients with first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2014, 56, 130-136.	3.1	13
68	Recognition of bipolar disorder type I before the first manic episode: challenges and developments. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 795-807.	2.8	11
69	Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 467-471.	3.1	32
70	Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment. <i>Psychiatry Research</i> , 2013, 210, 1290-1292.	3.3	11
71	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1376-1382.	3.1	84
72	Pharmacological and Psychosocial Management of Mental, Neurological and Substance Use Disorders in Low- and Middle-Income Countries: Issues and Current Strategies. <i>Drugs</i> , 2013, 73, 1549-1568.	10.9	13

#	ARTICLE	IF	CITATIONS
73	Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese. Trends in Psychiatry and Psychotherapy, 2013, 35, 62-75.	0.8	1
74	Pharmacological treatment of schizophrenia. International Review of Psychiatry, 2012, 24, 489-498.	2.8	10
75	Association of biomarkers and depressive symptoms in schizophrenia. Neuroscience Letters, 2011, 505, 282-285.	2.1	38